Abstract
BackgroundThe potential for astrocyte participation in central nervous system recovery is highlighted by in vitro experiments demonstrating their capacity to transdifferentiate into neurons. Understanding astrocyte plasticity could be advanced by comparing astrocytes with stem cells. RNA sequencing (RNA-seq) is ideal for comparing differences across cell types. However, this novel multi-stage process has the potential to introduce unwanted technical variation at several points in the experimental workflow. Quantitative understanding of the contribution of experimental parameters to technical variation would facilitate the design of robust RNA-Seq experiments.ResultsRNA-Seq was used to achieve biological and technical objectives. The biological aspect compared gene expression between normal human fetal-derived astrocytes and human neural stem cells cultured in identical conditions. When differential expression threshold criteria of |log2fold change| > 2 were applied to the data, no significant differences were observed. The technical component quantified variation arising from particular steps in the research pathway, and compared the ability of different normalization methods to reduce unwanted variance. To facilitate this objective, a liberal false discovery rate of 10% and a |log2fold change| > 0.5 were implemented for the differential expression threshold. Data were normalized with RPKM, TMM, and UQS methods using JMP Genomics. The contributions of key replicable experimental parameters (cell lot; library preparation; flow cell) to variance in the data were evaluated using principal variance component analysis. Our analysis showed that, although the variance for every parameter is strongly influenced by the normalization method, the largest contributor to technical variance was library preparation. The ability to detect differentially expressed genes was also affected by normalization; differences were only detected in non-normalized and TMM-normalized data.ConclusionsThe similarity in gene expression between astrocytes and neural stem cells supports the potential for astrocytic transdifferentiation into neurons, and emphasizes the need to evaluate the therapeutic potential of astrocytes for central nervous system damage. The choice of normalization method influences the contributions to experimental variance as well as the outcomes of differential expression analysis. However irrespective of normalization method, our findings illustrate that library preparation contributed the largest component of technical variance.
Highlights
The potential for astrocyte participation in central nervous system recovery is highlighted by in vitro experiments demonstrating their capacity to transdifferentiate into neurons
This finding is congruent with previous investigations that have illuminated the plastic capacity of astrocytes. Results from this Ribonucleic acid (RNA)-seq analysis stand in stark contrast to the results from microarray experiments that compare normal human fetal-derived astrocytes with human neural stem cells, where ~ 350 genes are reported to be upregulated by 5-fold in normal human fetal-derived astrocytes [33]
This discrepancy could be due to differences in technology (RNA-seq vs. microarray), or the number and type of replicate samples used for the statistical analyses, the differences in culture conditions are the most likely source of the different experimental outcomes
Summary
The potential for astrocyte participation in central nervous system recovery is highlighted by in vitro experiments demonstrating their capacity to transdifferentiate into neurons. RNA sequencing (RNA-seq) is ideal for comparing differences across cell types This novel multi-stage process has the potential to introduce unwanted technical variation at several points in the experimental workflow. Experiments have shown that the results of RNA-Seq experiments can be affected by technical aspects of data generation, including the quality and amount of RNA [10, 11] and library preparation [12,13,14] These experimental findings illustrate that the RNA-Seq outcomes can be confounded by the introduction of technical variation as part of sample processing during different phases of data acquisition and analysis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.